Country: Canada
Language: English
Source: Health Canada
TADALAFIL
MYLAN PHARMACEUTICALS ULC
G04BE08
TADALAFIL
20MG
TABLET
TADALAFIL 20MG
ORAL
4/30
Prescription
PHOSPHODIESTERASE TYPE 5 INHIBITORS
Active ingredient group (AIG) number: 0149485002; AHFS:
APPROVED
2016-07-12
_ _ _Page 1 of 52_ PRODUCT MONOGRAPH PR MYLAN-TADALAFIL Tadalafil Tablets, USP 2.5 mg, 5 mg Tablets (for _Once-a-day _use), 10 mg, 20 mg Tablets (for _“On-Demand” _dosing) cGMP-Specific Phosphodiesterase Type 5 Inhibitor TREATMENT OF ERECTILE DYSFUNCTION (ED) TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) TREATMENT OF ERECTILE DYSFUNCTION AND BENIGN PROSTATIC HYPERPLASIA (ED/BPH) Mylan Pharmaceuticals ULC 85 Advance Road Etobicoke, ON M8Z 2S6 Date of Revision: February 7, 2017 Submission Control No: 201793 _ _ _Page 2 of 52_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................ 3 SUMMARY PRODUCT INFORMATION ....................................................................... 3 INDICATIONS AND CLINICAL USE ............................................................................. 3 CONTRAINDICATIONS .................................................................................................. 4 WARNINGS AND PRECAUTIONS ................................................................................. 4 ADVERSE REACTIONS ................................................................................................... 8 DRUG INTERACTIONS ................................................................................................. 12 DOSAGE AND ADMINISTRATION ............................................................................. 15 OVERDOSAGE ............................................................................................................... 16 ACTION AND CLINICAL PHARMACOLOGY ........................................................... 17 STORAGE AND STABILITY ......................................................................................... 23 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 23 PART II: SCIENTIFIC INFORMATION ............................................................................... 24 PHARMACEUTICAL INFORMATION ........................................... Read the complete document